LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 195

Search options

  1. Article ; Online: Why do people die from COVID-19?

    Bastard, Paul

    Science (New York, N.Y.)

    2022  Volume 375, Issue 6583, Page(s) 829–830

    Abstract: Autoantibodies that neutralize type I interferons increase with age. ...

    Abstract Autoantibodies that neutralize type I interferons increase with age.
    MeSH term(s) Aging ; Antibodies, Neutralizing/blood ; Antibodies, Neutralizing/immunology ; Autoantibodies/blood ; Autoantibodies/immunology ; COVID-19/complications ; COVID-19/immunology ; COVID-19/mortality ; Humans ; Interferon Type I/immunology ; Patient Acuity ; Polyendocrinopathies, Autoimmune/complications ; Polyendocrinopathies, Autoimmune/immunology ; Virus Diseases/immunology
    Chemical Substances Antibodies, Neutralizing ; Autoantibodies ; Interferon Type I
    Language English
    Publishing date 2022-02-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.abn9649
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Le déficit en interférons de type I n’affecte pas la réponse immunitaire humorale au vaccin contre le SARS-CoV-2.

    Sokal, Aurélien / Bastard, Paul / Casanova, Jean-Laurent / Weill, Jean-Claude / Chappert, Pascal / Mahévas, Matthieu

    Medecine sciences : M/S

    2024  Volume 40, Issue 1, Page(s) 99–101

    Title translation Type I interferon deficiency does not impair humoral immune response to SARS-CoV-2 vaccination.
    MeSH term(s) Humans ; Immunity, Humoral ; COVID-19 Vaccines ; SARS-CoV-2 ; COVID-19/prevention & control ; Vaccination ; Antibodies, Viral
    Chemical Substances COVID-19 Vaccines ; Antibodies, Viral
    Language French
    Publishing date 2024-02-01
    Publishing country France
    Document type Journal Article
    ZDB-ID 632733-3
    ISSN 1958-5381 ; 0767-0974
    ISSN (online) 1958-5381
    ISSN 0767-0974
    DOI 10.1051/medsci/2023182
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia.

    Chauvineau-Grenier, Angélique / Bastard, Paul / Casanova, Jean-Laurent / Rossi, Benjamin

    Journal of clinical immunology

    2022  Volume 42, Issue 6, Page(s) 1107–1110

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Autoantibodies ; Humans ; COVID-19 Drug Treatment
    Chemical Substances Antibodies, Monoclonal, Humanized ; Autoantibodies ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2022-06-08
    Publishing country Netherlands
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 779361-3
    ISSN 1573-2592 ; 0271-9142
    ISSN (online) 1573-2592
    ISSN 0271-9142
    DOI 10.1007/s10875-022-01295-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Human autoantibodies underlying infectious diseases.

    Puel, Anne / Bastard, Paul / Bustamante, Jacinta / Casanova, Jean-Laurent

    The Journal of experimental medicine

    2022  Volume 219, Issue 4

    Abstract: The vast interindividual clinical variability observed in any microbial infection-ranging from silent infection to lethal disease-is increasingly being explained by human genetic and immunological determinants. Autoantibodies neutralizing specific ... ...

    Abstract The vast interindividual clinical variability observed in any microbial infection-ranging from silent infection to lethal disease-is increasingly being explained by human genetic and immunological determinants. Autoantibodies neutralizing specific cytokines underlie the same infectious diseases as inborn errors of the corresponding cytokine or response pathway. Autoantibodies against type I IFNs underlie COVID-19 pneumonia and adverse reactions to the live attenuated yellow fever virus vaccine. Autoantibodies against type II IFN underlie severe disease caused by environmental or tuberculous mycobacteria, and other intra-macrophagic microbes. Autoantibodies against IL-17A/F and IL-6 are less common and underlie mucocutaneous candidiasis and staphylococcal diseases, respectively. Inborn errors of and autoantibodies against GM-CSF underlie pulmonary alveolar proteinosis; associated infections are less well characterized. In individual patients, autoantibodies against cytokines preexist infection with the pathogen concerned and underlie the infectious disease. Human antibody-driven autoimmunity can interfere with cytokines that are essential for protective immunity to specific infectious agents but that are otherwise redundant, thereby underlying specific infectious diseases.
    MeSH term(s) Autoantibodies ; COVID-19 ; Candidiasis, Chronic Mucocutaneous/genetics ; Communicable Diseases ; Humans ; Pulmonary Alveolar Proteinosis
    Chemical Substances Autoantibodies
    Language English
    Publishing date 2022-03-23
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 218343-2
    ISSN 1540-9538 ; 0022-1007
    ISSN (online) 1540-9538
    ISSN 0022-1007
    DOI 10.1084/jem.20211387
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Human genetic and immunological determinants of critical COVID-19 pneumonia.

    Zhang, Qian / Bastard, Paul / Cobat, Aurélie / Casanova, Jean-Laurent

    Nature

    2022  Volume 603, Issue 7902, Page(s) 587–598

    Abstract: SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases. The ensuing risk of death (approximately 1% across age and gender) doubles ... ...

    Abstract SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases. The ensuing risk of death (approximately 1% across age and gender) doubles every five years from childhood onwards and is around 1.5 times greater in men than in women. Here we review the molecular and cellular determinants of critical COVID-19 pneumonia. Inborn errors of type I interferons (IFNs), including autosomal TLR3 and X-chromosome-linked TLR7 deficiencies, are found in around 1-5% of patients with critical pneumonia under 60 years old, and a lower proportion in older patients. Pre-existing auto-antibodies neutralizing IFNα, IFNβ and/or IFNω, which are more common in men than in women, are found in approximately 15-20% of patients with critical pneumonia over 70 years old, and a lower proportion in younger patients. Thus, at least 15% of cases of critical COVID-19 pneumonia can be explained. The TLR3- and TLR7-dependent production of type I IFNs by respiratory epithelial cells and plasmacytoid dendritic cells, respectively, is essential for host defence against SARS-CoV-2. In ways that can depend on age and sex, insufficient type I IFN immunity in the respiratory tract during the first few days of infection may account for the spread of the virus, leading to pulmonary and systemic inflammation.
    MeSH term(s) Age Distribution ; Autoantibodies/immunology ; COVID-19/genetics ; COVID-19/immunology ; COVID-19/mortality ; COVID-19/pathology ; Critical Illness ; Dendritic Cells/immunology ; Genome-Wide Association Study ; Humans ; Interferon Type I/genetics ; Interferon Type I/immunology ; Sex Distribution ; Toll-Like Receptor 3/deficiency ; Toll-Like Receptor 7/deficiency ; Toll-Like Receptor 7/genetics
    Chemical Substances Autoantibodies ; Interferon Type I ; TLR3 protein, human ; TLR7 protein, human ; Toll-Like Receptor 3 ; Toll-Like Receptor 7
    Language English
    Publishing date 2022-01-28
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/s41586-022-04447-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Artificial Intelligence in Nephrology: Core Concepts, Clinical Applications, and Perspectives.

    Niel, Olivier / Bastard, Paul

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2019  Volume 74, Issue 6, Page(s) 803–810

    Abstract: Artificial intelligence is playing an increasingly important role in many fields of medicine, assisting physicians in most steps of patient management. In nephrology, artificial intelligence can already be used to improve clinical care, hemodialysis ... ...

    Abstract Artificial intelligence is playing an increasingly important role in many fields of medicine, assisting physicians in most steps of patient management. In nephrology, artificial intelligence can already be used to improve clinical care, hemodialysis prescriptions, and follow-up of transplant recipients. However, many nephrologists are still unfamiliar with the basic principles of medical artificial intelligence. This review seeks to provide an overview of medical artificial intelligence relevant to the practicing nephrologist, in all fields of nephrology. We define the core concepts of artificial intelligence and machine learning and cover the basics of the functioning of neural networks and deep learning. We also discuss the most recent clinical applications of artificial intelligence in nephrology and medicine; as an example, we describe how artificial intelligence can predict the occurrence of progressive immunoglobulin A nephropathy. Finally, we consider the future of artificial intelligence in clinical nephrology and its impact on medical practice, and conclude with a discussion of the ethical issues that the use of artificial intelligence raises in terms of clinical decision making, physician-patient relationship, patient privacy, and data collection.
    MeSH term(s) Algorithms ; Artificial Intelligence ; Female ; Forecasting ; Humans ; Machine Learning ; Male ; Nephrology/methods ; Nephrology/trends ; Quality Improvement
    Language English
    Publishing date 2019-08-23
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2019.05.020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Artificial intelligence improves estimation of tacrolimus area under the concentration over time curve in renal transplant recipients.

    Niel, Olivier / Bastard, Paul

    Transplant international : official journal of the European Society for Organ Transplantation

    2018  Volume 31, Issue 8, Page(s) 940–941

    MeSH term(s) Area Under Curve ; Humans ; Immunosuppressive Agents/pharmacokinetics ; Kidney Transplantation ; Neural Networks (Computer) ; Tacrolimus/pharmacokinetics
    Chemical Substances Immunosuppressive Agents ; Tacrolimus (WM0HAQ4WNM)
    Language English
    Publishing date 2018-05-11
    Publishing country England
    Document type Letter
    ZDB-ID 639435-8
    ISSN 1432-2277 ; 0934-0874
    ISSN (online) 1432-2277
    ISSN 0934-0874
    DOI 10.1111/tri.13271
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality.

    Troya, Jesús / Bastard, Paul / Casanova, Jean-Laurent / Abel, Laurent / Pujol, Aurora

    Journal of clinical immunology

    2022  Volume 42, Issue 4, Page(s) 738–741

    MeSH term(s) Antibodies, Neutralizing ; Autoantibodies ; Biomarkers ; COVID-19 ; Humans ; Lymphocytes ; SARS-CoV-2
    Chemical Substances Antibodies, Neutralizing ; Autoantibodies ; Biomarkers
    Language English
    Publishing date 2022-03-03
    Publishing country Netherlands
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 779361-3
    ISSN 1573-2592 ; 0271-9142
    ISSN (online) 1573-2592
    ISSN 0271-9142
    DOI 10.1007/s10875-022-01241-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Type I interferons and SARS-CoV-2: from cells to organisms.

    Bastard, Paul / Zhang, Qian / Zhang, Shen-Ying / Jouanguy, Emmanuelle / Casanova, Jean-Laurent

    Current opinion in immunology

    2022  Volume 74, Page(s) 172–182

    Abstract: Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various ... ...

    Abstract Type I interferons (IFNs) have broad and potent antiviral activity. We review the interplay between type I IFNs and SARS-CoV-2. Human cells infected with SARS-CoV-2 in vitro produce low levels of type I IFNs, and SARS-CoV-2 proteins can inhibit various steps in type I IFN production and response. Exogenous type I IFNs inhibit viral growth in vitro. In various animal species infected in vivo, type I IFN deficiencies underlie higher viral loads and more severe disease than in control animals. The early administration of exogenous type I IFNs improves infection control. In humans, inborn errors of, and auto-antibodies against type I IFNs underlie life-threatening COVID-19 pneumonia. Overall, type I IFNs are essential for host defense against SARS-CoV-2 in individual cells and whole organisms.
    MeSH term(s) Animals ; COVID-19/immunology ; Humans ; Interferon Type I/immunology ; SARS-CoV-2/immunology
    Chemical Substances Interferon Type I
    Language English
    Publishing date 2022-01-25
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1035767-1
    ISSN 1879-0372 ; 0952-7915
    ISSN (online) 1879-0372
    ISSN 0952-7915
    DOI 10.1016/j.coi.2022.01.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Impact of non-antibiotic drugs on the human intestinal microbiome.

    Le Bastard, Quentin / Berthelot, Laureline / Soulillou, Jean-Paul / Montassier, Emmanuel

    Expert review of molecular diagnostics

    2021  Volume 21, Issue 9, Page(s) 911–924

    Abstract: Introduction: The gut microbiota is composed of trillions of microbial cells and viruses that interact with hosts. The composition of the gut microbiota is influenced by several factors including age, diet, diseases, or medications. The impact of drugs ... ...

    Abstract Introduction: The gut microbiota is composed of trillions of microbial cells and viruses that interact with hosts. The composition of the gut microbiota is influenced by several factors including age, diet, diseases, or medications. The impact of drugs on the microbiota is not limited to antibiotics and many non-antibiotic molecules significantly alter the composition of the intestinal microbiota.
    Areas covered: This review focuses on the impact of four of the most widely prescribed non-antibiotic drugs in the world: Proton-pump inhibitors, metformin, statins, and non-steroidal anti-inflammatory. We conducted a systematic review by searching online databases including Medline, Web of science, and Scopus for indexed articles published in English until February 2021. We included studies assessing the intestinal microbiome alterations associated with proton pump inhibitors (PPIs), metformin, statins, and nonsteroidal anti-inflammatory drugs (NSAIDs). Only studies using culture-independent molecular techniques were included.
    Expert opinion: The taxonomical signature associated with non-antibiotic drugs are not yet fully described, especially in the field of metabolomic. The identification of taxonomic profiles associated a specific molecule provides information on its mechanism of action through interaction with the intestinal microbiota. Many side effects could be related to the dysbiosis induced by these molecules.
    MeSH term(s) Anti-Bacterial Agents/adverse effects ; Dysbiosis/chemically induced ; Gastrointestinal Microbiome ; Humans ; Microbiota ; Proton Pump Inhibitors/adverse effects
    Chemical Substances Anti-Bacterial Agents ; Proton Pump Inhibitors
    Language English
    Publishing date 2021-07-15
    Publishing country England
    Document type Journal Article ; Systematic Review
    ZDB-ID 2112530-2
    ISSN 1744-8352 ; 1473-7159
    ISSN (online) 1744-8352
    ISSN 1473-7159
    DOI 10.1080/14737159.2021.1952075
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top